Cargando…

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3 that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mollazadegan, Kazhan, Skogseid, Britt, Botling, Johan, Åkerström, Tobias, Eriksson, Barbro, Welin, Staffan, Sundin, Anders, Crona, Joakim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942326/ https://www.ncbi.nlm.nih.gov/pubmed/35148276 http://dx.doi.org/10.1530/EC-21-0604

Ejemplares similares

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
por: Zhang, Liang, et al.
Publicado: (2023)

PET-Guided Surgery — High Correlation between Positron Emission Tomography with (11)C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours
por: Örlefors, Håkan, et al.
Publicado: (2012)

RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective
por: Crona, Joakim, et al.
Publicado: (2018)

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE
por: Pettersson, Olof Joakim, et al.
Publicado: (2021)

Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
por: Pettersson, Olof, et al.
Publicado: (2020)

Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line
por: Monazzam, Azita, et al.
Publicado: (2020)

Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study
por: Kjaer, Josefine, et al.
Publicado: (2022)

Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
por: Garske-Román, Ulrike, et al.
Publicado: (2018)

Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma
por: Garske, Ulrike, et al.
Publicado: (2012)

Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma
por: Crona, Joakim, et al.
Publicado: (2015)

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
por: Papantoniou, Dimitrios, et al.
Publicado: (2023)

Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation
por: Kjaer, Josefine, et al.
Publicado: (2022)

Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases
por: Kjaer, J, et al.
Publicado: (2021)

Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma
por: Crona, Joakim, et al.
Publicado: (2013)

Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
por: Papantoniou, Dimitrios, et al.
Publicado: (2020)

(11)C-hydroxy-ephedrine-PET/CT in the Diagnosis of Pheochromocytoma and Paraganglioma
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Recent developments in imaging of pancreatic neuroendocrine tumors
por: Kartalis, Nikolaos, et al.
Publicado: (2015)

Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors
por: Thiis‐Evensen, Espen, et al.
Publicado: (2022)

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
por: Ali, Abir Salwa, et al.
Publicado: (2017)

Advances in adrenal tumors 2018
por: Crona, J, et al.
Publicado: (2018)

Quadruple Bioprosthetic Valve Replacement in a Patient With Severe Carcinoid Heart Disease
por: Albåge, Anders, et al.
Publicado: (2020)

Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission
por: Juhlin, Carl Christofer, et al.
Publicado: (2020)

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
por: Ali, Abir Salwa, et al.
Publicado: (2018)

Poor Prognosis of Grade 2 Spread Through Air Spaces in Neuroendocrine Tumors
por: Chae, Mincheol, et al.
Publicado: (2022)

Identification of Achaete-scute complex-like 1 (ASCL1) target genes and evaluation of DKK1 and TPH1 expression in pancreatic endocrine tumours
por: Johansson, Térèse A, et al.
Publicado: (2009)

Prognostic Relevance of Survivin in Pancreatic Endocrine Tumors
por: Ekeblad, Sara, et al.
Publicado: (2011)

A real-life treatment cohort of pancreatic neuroendocrine tumors: High-grade increase in metastases confers poor survival
por: Zhang, Wu-Hu, et al.
Publicado: (2022)

Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment
por: Lamarca, Angela, et al.
Publicado: (2021)

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
por: La Rosa, Stefano
Publicado: (2021)

Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration
por: Razmara, Masoud, et al.
Publicado: (2018)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

DNA building blocks: keeping control of manufacture
por: Hofer, Anders, et al.
Publicado: (2012)

Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
por: Marchese, Ugo, et al.
Publicado: (2022)

Low Grade Neuroendocrine Tumors of the Lung
por: Melosky, Barbara
Publicado: (2017)

Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
por: Jahn, Ulrika, et al.
Publicado: (2021)

Type-1 Grade 2 Multi-Focal Gastric Neuroendocrine Tumors Secondary to Chronic Autoimmune Gastritis
por: Yu, Ziqi, et al.
Publicado: (2022)

Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 /PET
por: Monazzam, Azita, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r2p79p605eaa19mbi6tsd1e34v